.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,884,136

« Back to Dashboard

Details for Patent: 7,884,136

Title:Modified-release formulations of a bupropion salt
Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Inventor(s): Oberegger; Werner (Mississauga, CA), Zhou; Fang (Davie, FL), Maes; Paul (Caluire et Cuire, FR), Turchetta; Stefano (Rome, IT), Jackson; Graham (Celbridge, IE), Massardo; Pietro (Roma, IT), Saleh; Mohammad Ashty (Oakville, CA)
Assignee: Biovail Laboratories International S.R.L. (St. Michael, BB)
Filing Date:Jun 27, 2006
Application Number:11/993,723
Claims:1. A composition, comprising at least one pharmaceutically acceptable excipient; and two or more of the following crystalline compounds: (i) a crystalline compound of the formula: ##STR00004## exhibiting an X-ray powder diffraction pattern with an X-ray source of Cu/30 kV and having characteristic peaks at about 6.70 .degree.2Theta, about 12.51 .degree.2Theta, about 19.60 .degree.2Theta, about 22.93 .degree.2Theta and about 26.11 .degree.2Theta; (ii) a crystalline compound of the formula: ##STR00005## exhibiting an X-ray powder diffraction pattern with an X-ray source of Cu/30 kV and having characteristic peaks at about 6.53 .degree.2Theta, about 13.03 .degree.2Theta, about 15.91 .degree.2Theta, about 16.52 .degree.2Theta and about 23.11 .degree.2Theta; and (iii) a crystalline compound of the formula: ##STR00006## exhibiting an X-ray powder diffraction pattern with an X-ray source of Cu/30 kV and having characteristic peaks at about 8.06 .degree.2Theta, about 12.28 .degree.2Theta, about 16.00 .degree.2Theta, about 18.07 .degree.2Theta and about 25.12 .degree.2Theta.

2. The composition according to claim 1, comprising three of the crystalline compounds.

3. A composition, comprising at least one pharmaceutically acceptable excipient; and two or more of the following crystalline compounds: (i) a crystalline compound of the formula: ##STR00007## exhibiting an X-ray powder diffraction pattern with an X-ray source of Cu/30 kV and having five or more characteristic peaks selected from the group consisting of about 6.70 .degree.2Theta, about 12.51 .degree.2Theta, about 13.83 .degree.2Theta, about 19.60 .degree.2Theta, about 22.93 .degree.2Theta, about 23.98 .degree.2Theta, about 24.76 .degree.2Theta, about 25.51 .degree.2Theta, about 26.11 .degree.2Theta and about 32.70 .degree.2Theta; (ii) a crystalline compound of the formula: ##STR00008## exhibiting an X-ray powder diffraction pattern with an X-ray source of Cu/30 kV and having five or more characteristic peaks selected from group consisting of about 6.53 .degree.2Theta, about 13.03 .degree.2Theta, about 15.91 .degree.2Theta, about 16.52 .degree.2Theta, about 21.95 .degree.2Theta, about 23.11 .degree.2Theta, about 25.83 .degree.2Theta, about 26.83 .degree.2Theta, about 28.81 .degree.2Theta and about 32.42 .degree.2Theta; and (iii) a crystalline compound of the formula: ##STR00009## exhibiting an X-ray powder diffraction pattern with an X-ray source of Cu/30 kV and having five or more characteristic peaks selected from the group consisting of about 8.06 .degree.2Theta, about 12.28 .degree.2Theta, about 16.00 .degree.2Theta, about 18.07 .degree.2Theta, about 19.67 .degree.2Theta, about 23.42 .degree.2Theta, about 24.24 .degree.2Theta, about 25.12 .degree.2Theta, about 28.99 .degree.2Theta and about 29.66 .degree.2Theta.

4. The composition according to claim 3, comprising three of the crystalline compounds.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc